Pharma Focus Asia

Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery Research

Friday, October 11, 2019

Advaxis, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a research collaboration agreement with the University of California Los Angeles (UCLA) to conduct preclinical studies evaluating the Company’s Lm technology in mouse tumor models of glioblastoma multiforme (GBM). Specifically, the collaboration with Dr. Vaithi Arumugaswami’s group at UCLA’s Department of Molecular and Medical Pharmacology will investigate anti-tumor immunity and anti-tumor responses generated by Lm vaccines that express diverse glioblastoma neoantigens.

“We are excited that Dr. Arumugaswami and his colleagues at UCLA will investigate the potential of our Lm technology platform in GBM, one of the deadliest cancers,” said Andres Gutierrez, Executive Vice President and Chief Medical Officer of Advaxis. “Contrary to other tumor types, GBM has not seen much success in targeting by immunotherapeutic agents due to a low tumor mutation burden, high tumor heterogeneity and presence of the blood brain barrier, among other factors. Hence, Dr. Arumugaswami’s characterization of the neoantigen landscape and immune responses to Lm- constructs may lead to the development of novel therapies with clinical activity in this elusive cancer.”

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024